What Medications Work Fastest for Gout?

Gout is a form of inflammatory arthritis caused by the deposition of monosodium urate crystals in joints and surrounding tissues, typically triggered by chronic hyperuricemia. Effective management requires both acute flare control and long-term uric acid–lowering therapy—neither approach alone is sufficient for optimal outcomes.

For acute gout flares, first-line pharmacologic treatment includes nonsteroidal anti-inflammatory drugs (NSAIDs) such as indomethacin or naproxen, administered at full anti-inflammatory doses early in the attack. Colchicine remains an effective alternative, particularly when initiated within 24 hours of symptom onset; low-dose regimens (e.g., 0.6 mg twice daily) are now preferred over high-dose protocols due to improved safety and comparable efficacy. In patients with contraindications to NSAIDs or colchicine—or those with polyarticular, severe, or refractory flares—short-course oral corticosteroids (e.g., prednisone 30–40 mg daily for 3–5 days, followed by taper) are strongly recommended. Intra-articular glucocorticoid injection may be considered for monoarticular involvement.

Long-term management focuses on urate-lowering therapy (ULT) to achieve and maintain serum uric acid levels below 6.0 mg/dL (360 µmol/L), or below 5.0 mg/dL (300 µmol/L) in patients with tophi or frequent flares. Xanthine oxidase inhibitors—allopurinol (first-line) and febuxostat—are the most widely used agents. Allopurinol dosing must be titrated gradually (starting at 100 mg/day, increasing every 2–4 weeks) and adjusted for renal function; HLA-B*58:01 genotyping is advised in high-risk populations (e.g., Han Chinese, Korean, Thai) before initiation to mitigate risk of severe cutaneous adverse reactions. Febuxostat is reserved for patients intolerant or unresponsive to allopurinol, with caution advised in those with cardiovascular disease.

Uricosuric agents like lesinurad (used adjunctively with xanthine oxidase inhibitors) and probenecid (in patients with normal renal function and no nephrolithiasis) offer additional options. Pegloticase—a recombinant uricase enzyme—is indicated for refractory gout with tophi unresponsive to conventional ULT, though its use requires careful monitoring for infusion reactions and antibody development.

Importantly, initiating ULT during an active flare is safe and encouraged when appropriate anti-inflammatory prophylaxis (e.g., low-dose colchicine for at least 6 months) is provided. Rapid uric acid reduction without prophylaxis increases flare risk, underscoring the necessity of integrated, individualized treatment strategies grounded in current evidence-based guidelines.